Mais les résultats doivent être attendus longtemps et il n'y a généralement pas de temps metronidazole prix L'autre cas, c'est que l'achat d'un ou d'un autre antibiotique dans une pharmacie classique nécessite des dépenses matérielles considérables et pas toutes les personnes ne peuvent acheter des produits pharmaceutiques aussi coûteux.

Microsoft word - dranitsaris_publications.docx

GEORGE DRANITSARIS

PUBLICATIONS

1.
Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer 2012 Apr 27. Dranitsaris G, Jelincic V, Choe Y. Meta-Regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events. Clinical and Applied Thrombosis and Hemostasis 2012 Mar 2. Dranitsaris G, Vincent M, Yu j, et al. Development and validation of a prediction index for hand foot skin reaction in cancer patients receiving sorafenib. Annals of Oncology 2012, Jan 6. Dranitsaris G, Truter I, Lubbe MS. The development of a value based pricing index for new drugs in metastatic colorectal cancer. European Journal of Cancer 2011;47:1299-304. Dranitsaris G, Amir E, Dorward K. Biosimilars of Protein Based Drug Therapies: Regulatory, Clinical and Commercial Considerations. Drugs 2011;71:1527-36. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Supportive Care in Cancer 2011 Jul 22. Dranitsaris G, Jelincic V, Choe Y. Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement. Thrombosis Journal 2011;9:3 Dranitsaris G, Truter I, Lubbe M et al. Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. International Journal of Technology Assessment in Health Care 2011;27:23-30. Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: A cost effectiveness analysis. Supportive Care in Cancer 2011;19:1807-13. 10. Dranitsaris G, Truter I, Lubbe M. The application of pharmacoeconomic modeling to estimate a value based price for new cancer drugs. Journal of Evaluation in Clinical Practice November 18, 2010. George Dranitsaris
11. Dranitsaris G, Truter I, Lubbe MS, et al. Advances in cancer therapeutics and patient access to new drugs. Pharmacoeconomics 2011;29:213-24. 12. Dranitsaris G, Edwards S, Edwards J, et al. Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: An assessment of safety and efficacy in the Canadian province of Newfoundland and Labrador. Current Oncology 2010;17:12-6. 13. Dranitsaris G, Joy A, Young S, et al. Identifying patients at high risk for nausea and vomiting after chemotherapy: The development of a practical prediction tool. Journal of Supportive Oncology 2009;7:W1-8. 14. Dranitsaris G, Coleman, Gradishar W. nab-paclitaxel weekly or Q3W compared to docetaxel Q3W as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Research and Treatment 2010;119:717-24. 15. Freedman O, Amir E, Dranitsaris G, et al. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Research and Treatment 2010;119:155-61. 16. Hatzimichael E, Dranitsaris G, Dasoula A et al. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clinical Lymphoma and Myeloma 2009;9:239-42. 17. Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Applied Health Economics and Health Policy 2009;7:43-59. 18. Vincent MD, Dranitsaris G. The price function of toxicity. Lancet Oncology 19. Dranitsaris G, Selby P, Negrete, JC. Meta analysis of placebo control ed trials of acamprosate for the treatment of alcohol dependence. Journal of Addiction Medicine 2009;3:74-82. 20. Dranitsaris G, Stumpo C, Smith R and Bartle W. Cost-utility analysis of extended dalteparin prophylaxis for venous thromboembolic events in patients undergoing major orthopedic surgery. American Journal of Cardiovascular Drugs 2009;9:45-58. 21. Dranitsaris G, Cottrel W, Spirovski B, Hopkins S. Economic analysis of albumin- bound paclitaxel for the treatment of metastatic breast cancer. Journal of Oncology Pharmacy Practice 2009;15:67-78. 22. Dranitsaris G, Rayson D, Vincent M, et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: The development of a prediction model. American Journal of Clinical Oncology 2008;31:369-74. George Dranitsaris
23. Dranitsaris G, Rayson D, Vincent M, et al. The development of a prediction model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Research and Treatment 2008;107:443-50. 24. Stebbing J, Dranitsaris G, Vincent M. Chemotherapy-Induced Toxicity in the Community Oncology Setting: Hear No Evil, See No Evil. Editorial: British Medical Journal Dec 6; 2007. 25. Booth CM, Clemons M, Dranitsaris G et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. Journal of Supportive Oncology 2007;5:374-80. 26. Booth CM, Dranitsaris G, Gainford MC, et al. External influences and priority- setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer. BMC Cancer. 2007 Jun 28;7:110. 27. Clemons M, Dranitsaris G, Ooi W, Cole DEC. A phase II trial evaluating the pal iative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event or progressive bone metastases despite standard bisphosphonate therapy. Breast Cancer Research and Treatment 2008;108:79-85. 28. Verma S, Wong NS, Trudeau M, Joy A, Mackey J, Dranitsaris G, Clemons M. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. American Journal of Clinical Oncology 2007;30:297-302. 29. Dranitsaris G, Shah A, Spirovski B, Vincent M. Severe diarrhea in patients with advanced colorectal Cancer receiving FOLFOX of FOLFIRI chemotherapy: development of a risk prediction tool. Clinical Colorectal Cancer 2007;6:367-73. 30. Vincent M, Dranitsaris G, Verma S et al. The development of a prediction tool for chemotherapy-induced anemia in patients with advanced non smal cel lung cancer receiving pal iative chemotherapy. Supportive Care in Cancer 2007;15:265-72. 31. Clemons M, Dranitsaris G, Ooi W, et al. A Phase II trial evaluating the palliative benefit of second line zoledronic acid in breast cancer patients with either a skeletal related event or progressive bone metastases despite first line bisphosphonate therapy. Journal of Clinical Oncology 2006;24:1-6. 32. Canadian Surgical Wait Times Initiative. Consensus document: Recommendations for optimal surgical wait times for patients with urological malignancies. Canadian Journal of Urology 2006;13: (suppl 3) 62-4. 33. Fleshner N, Dranitsaris G, Finel i A, et al. Surgical wait times for patients with urological cancers: A survey of Canadian surgeons. Journal of Urology 2006;13: (suppl 3) 3-13. George Dranitsaris
34. Dranitsaris G, Vincent M, Crowther M. Dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: A pharmacoeconomic analysis. Pharmacoeconomics 2006;24:593-607. 35. Dranitsaris G, Maroun J, Chiritescu G, et al. The development of a prediction tool for severe diarrhea in patients with colorectal cancer receiving chemotherapy. Support and Pal iative Cancer Care Journal 2006;2:127-34. 36. Dranitsaris G, Clemons M, Verma S et al. The development of a prediction tool for anemia in breast cancer patients receiving adjuvant chemotherapy. Lancet Oncology 2005;6:856-63. 37. Dranitsaris G, Johnson M, Poirier S et al. Are health care providers who work with cancer drugs at an increased risk for toxic events?: A systematic review and meta analysis of the literature. Journal of Oncology Pharmacy Practice 2005;11:69-73. 38. Dranitsaris G, Mil iken D, Zanke B, Evans WK. The impact of practice guidelines and funding policies on the uptake of new chemotherapy drugs for the treatment of advanced non-smal cel lung cancer. Journal of Evaluation in Clinical Practice 2005;11:350-56. 39. Dranitsaris G, Maroun J and Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: A cost of il ness analysis. Supportive Care in Cancer 2005;13:18-24. 40. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. British Medical Jounral 2005;330:769-73. 41. Rakovitch E, Pignol JP, Chartier C, Ezer M, Verma S, Dranitsaris G, Clemons M. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Research and Treatment 2005;90:139-148. 42. Dranitsaris G, Maroun J and Shah A. Estimating the cost of il ness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Canadian Journal of Gastroenterology 2005;19:83-7. 43. Dranitsaris G, Kahn S, Stumpo C, et al. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients. American Journal of Cardiovascular Drugs 2004; 2004;4:325-33. 44. Dranitsaris G, Leung PP. Using decision analysis modelling to determine pricing of new pharmaceuticals: The case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy. International Journal of Technology Assessment in Health Care 2004;20:289-95. George Dranitsaris
45. Verma S, Kerr-Cresswel D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M. Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical Oncologists. Supportive Care in Cancer 2004;12:852-58. 46. Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kerr-Cresswel D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrel W, Dranitsaris G. Do physicians fol ow systemic treatment and funding policy guidelines? Canadian Journal of Clinical Pharmacology 2004 Spring;11:e168-78. 47. Dranitsaris G (co-author) and member of the Anemia Review Panel. Guidelines for the management of anemia. 1st ed. Toronto: MUMS Guideline Clearinghouse; 2004. 48. Dranitsaris G, Elia-Pacitti J Cottrel C. Measuring treatment preferences and wil ingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics 2004;22:375-87. 49. Perelman VS, Francis GJ, Rutledge T, Foote J, Martino F, Dranitsaris G. Sterile versus nonsterile gloves for repair of uncomplicated lacerations in the emergency department: A randomized control ed trial. Annals of Emergency Medicine. 2004;43:362-70. 50. Clemons M, Wright F, McWhirter E, Dranitsaris G. Baseline radiological staging in early breast cancer: A comparison of practice guideline recommendations with actual clinical practice. Breast 2003;Suppl 1:S20 51. Clemons M, Dranitsaris G, Charbonneau F, et al. How important are hematopoietic growth factors for maintaining dose intensity of adjuvant chemotherapy for breast cancer? Current Oncology 2003:10;1-6. 52. Dranitsaris G, Norris B, Hanna W, et al. Identifying the optimal timing of HER-2 testing in patients with breast cancer: A Canadian economic evaluation. Current Oncology 2003;10:36-44. 53. Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of first line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to tamoxifen. American Journal of Clinical Oncology 2003;23:289-96. 54. Dranitsaris G, Cottrel W, Evans WK. The cost effectiveness of chemotherapy for non-smal cel lung cancer. Current Opinion in Oncology 2002;14:375-383. 55. Schimmer AD, Dranitsaris G, Ali V, et al. The autologous blood and marrow transplant long-term fol ow-up clinic: a model of care for fol owing and treating survivors of autotransplant. Suppotive Care in Cancer 2002;10:247-52. 56. Dranitsaris G, Castel LD, Baladi JF, Shulman KA. Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysis. Journal of Oncology Pharmacy Practice 2001;7:27-33. George Dranitsaris
57. Dranitsaris G, Leung P and Warr D. Implementing evidence based guidelines in the oncology setting: results of a four-month prospective intervention study. Supportive Carein Cancer 2001;9:611-18. 58. Dranitsaris G, Leung P, Ciotti R, et al. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. Pharmacoeconomics 2001;19:955-67. 59. Dranitsaris G, Spizzirri D, Pitre M, McGeer A. A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals. International Journal of Technology Assessment in Health Care 2001;17:171-80. 60. Dranitsaris G, Leung PP, Mather J, Oza A. Cost utility analysis of second line hormonal therapy in advanced breast cancer: A comparison of two aromatase inhibitors to megestrol acetate. Anti-Cancer Drugs 2000;11:591-601. 61. Dranitsaris G, Longo CJ, Grossman L. Measuring the economic value of a new insulin preparation (Humalog Mixture 25): A wil ingness-to-pay approach. Pharmacoeconomics 2000;18:275-87. 62. Dranitsaris G. The cost of blood transfusions in cancer patients: A reanalysis of a Canadian economic evaluation. Journal of Oncology Pharmacy Practice 2000;6:37-42. 63. Blomqvist A, Crabbé P, Dranitsaris G, Lanoie P. Final report of health impacts of green house gas mitigation measures. Climate Change and Health Economics Advisory Panel. Health Canada Publication, January 2000. 64. Leung P, Tanock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost utility analysis of chemotherapy using paclitaxel, docetaxel or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 1999;17:3082-90. 65. Dranitsaris G. Clinical and economic considerations of empiric antibiotic therapy of febrile neutropenia in cancer patients. Pharmacoeconomics 1999;16:343-53. 66. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-79. 67. Dranitsaris G. Pamidronate for the prevention of skeletal related events in multiple myeloma: What does the public think it's worth. Int J Tech Assessment Health Care 1999;15:108-22. 68. Ortega A., Dranitsaris G., Puodziunas A. What are cancer patients willing to pay for epoetin alfa: A cost-benefit analysis. Cancer 1998;83:2588-96. George Dranitsaris
69. Couban S, Dranitsaris G, Andreou P, et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: A Canadian perspective. Bone Marrow Transplant 1998;22:199-1205. 70. Dranitsaris G. Treatment of Non-Hodgkin's Lymphoma: A review. Anti-Cancer 71. Dranitsaris G. Statistical methods in clinical research: A review for pharmacists. Journal of Oncology Pharmacy Practice 1998;4:151-8. 72. Dranitsaris G, Phillips P, Rotstein C, et al. Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. Pharmacoeconomics 1998;13:509-18. 73. Dranitsaris G, MacDonald K, McGeer A. The rational use of antibiotics: The Princess Margaret Hospital experience: Can J Infect Dis 1998; 9: 41-2. 74. Ortega A, Dranitsaris G, Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Tech Assessment Health Care 1998; 14: 788-98. 75. Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: An assessment of amifostine cytoprotection. Support Care Cancer 1997;5:489-99. 76. Ortega A, Dranitsaris G, Sturgeon J, et al. Cost utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997;66:454-63. 77. Dranitsaris G, Altmayer C, Quirt I. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor in CHOP chemotherapy for Non-Hodgkin's Lymphoma. Pharmacoeconomics 1997;11:566-577. 78. Dranitsaris G. G-CSF in the community setting: Oncology agent offers opportunity for community pharmacists. Pharmacy Practice 1996;12:79-84. 79. Dranitsaris G. Managing drug costs in the oncology setting: A possible solution to decreased funding for hospitals. Oncology Advisor 1996;3:3-4. 80. Dranitsaris G. Tran TM. Economic analyses of toxicity secondary to anthracycline based breast cancer chemotherapy. European Journal of Cancer 1995;31A:2174-80. 81. Dranitsaris G, DeAngelis C, Warr D, Narine L. Pharmacoeconomic analysis of prophylactic treatments for emesis secondary to breast cancer chemotherapy. Canadian Journal of Hospital Pharmacy 1995;48:266-75. George Dranitsaris
82. Dranitsaris G, Warr D, Puodziunas A. A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Supportive Care in Cancer 1995;3:183-89. 83. Dranitsaris G., Tran TM, McGeer AJ, Narine L. Pharmacoeconomic analysis of empiric therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 1995;7:49-62. 84. Dranitsaris G, Sutcliffe SB. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leukmia and Lymphoma 1995;17:139-45. 85. Dranitsaris G. Piperacillin/tazobactam: For the management of intra-abdominal infections. Focus on New Drugs 1994;13:12-19. 86. Dranitsaris G, Pilla NJ, McGeer AJ. A vancomycin drug use evaluation and economic analysis in a cancer treatment centre. Canadian Journal of Hospital Pharmacy 1994;47:59-64. 87. Walker SE, Paton, TW, Cowan DH, Manual MA, Dranitsaris G. Bioavailability of Iron in oral ferrous sulphate preparations in healthy volunteers. Canadian Medical Association Journal 1989;14:543-547. 88. Walker SE, Dranitsaris G. Stability of reconstituted ceftazidime in dextrose and saline solutions. Canadian Journal of Hospital Pharmacy 1988;41:65-72. 89. Walker SE, Dranitsaris G. Stability of reconstituted ceftriaxone in dextrose and saline solutions. Canadian Journal of Hospital Pharmacy 1987;40:161-166.

Source: http://www.med.uoi.gr/haematology/Dranitsaris_Publications.pdf

Pii: s1049-3867(01)00141-4

The Delivery of Medical Abortion Services: The Views of Experienced Providers Linda J. Beckman, PhD California School of Professional Psychology Alliant University Los Angeles, California S. Marie Harvey, DrPH Center for the Study of Women in Society University of Oregon Eugene, Oregon Sarah J. Satre, MA Applied Research Northwest Bellingham, Washington Abstract This study examined bel

elledici.org

OCCHIO ALL'IMPREVISTO HUG: L'allegra compagnia aveva trascorso delle ore davvero meravigliose. Soprattutto, da semplici conoscenti si erano trasformati in amici. Squit aveva raccontato a tutti la sua storia: come e perché se ne era andato di casa, la scoperto dello sbaglio e il suo desiderio di rivedere Papa, Mama e Bog. Restavano ancora poche ore di luce, prima che la notte stendesse

Copyright © 2010-2014 Medical Science